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mPGES-1 is involved in both  
renal and central mechanisms  
of volume control
Jia et al., Am J Physiol Renal Physiol 2010; 299: F155–F166; doi:10.1152/
ajprenal.90702.2008
Prostaglandins (PGs) contribute to the regulation of renal 
function at many levels, including sodium, chloride, and 
water transport along the nephron, renal blood flow, glomeru-
lar filtration, renin secretion, and so on. PGE2, the major PG 
produced in the kidney, can inhibit sodium and water reabsorp-
tion, and, conversely, nonselective inhibitors of cyclo oxygenase 
(COX) as well as COX-2-selective inhibitors are well known to 
induce volume retention and, secondarily, hyper tension. Three 
forms of PGE synthase (PGES) have been isolated: microsomal 
PGES (mPGES)-1, mPGES-2, and cytosolic PGES, of which 
mPGES-1 is the best characterized. Previous studies had found 
that salt loading increased mPGES-1 protein expression in the 
distal nephron, and that when a high-salt diet was given to 
mice with deletion of the enzyme’s gene (mPGES-1–/– mice), 
they developed excessive volume retention and hyper tension, 
indicating that mPGES-1 has a critical role in the adaptation 
to high salt intake. In a recent communication, Jia et al. further 
examined the role of mPGES-1 in the control of extracellular 
fluid volume by focusing on the body’s response to miner-
alocorticoids excess. As expected, they found that a 2-week 
infusion of aldosterone to mice receiving a normal salt intake 
caused transient (in days 1 and 2) sodium retention, but oth-
erwise, sodium and water balances, hematocrit, and body 
weight were not significantly changed. This ‘escape’ from the 
sodium-retaining effect of aldosterone was associated with 
increases in urinary PGE2 excretion, induction of mPGES-1 
in the proximal tubules (absent when aldosterone was given 
with a low-sodium diet), plus a widespread downregulation of 
the mRNA of the NH3, NKCC2, and NCC transporters as well 
as the epithelial sodium channel and aquaporin 2 (Figure). In 
marked contrast, in mPGES-1–/– mice, aldosterone administra-
tion increased sodium and water balance and body weight, and 
it induced hyperosmolality (as evidenced by hypernatremia). 
In addition, there was no downregulation of the mRNA of the 
ion transporters and of the sodium channel and aquaporin 
(Figure) as was seen in wild-type mice. Of great interest was 
the additional finding that when compared with wild-type 
mice, mPGES-1–/– mice had marked increases in sodium (and 
water) intake during aldosterone infusion. Hence, the study 
further solidifies the critical role of mPGES-1 and PGE2 in 
the body’s response to excess extracellular fluid volume and 
shows that this role involves effects both in the kidney and in 
the central nervous system.
Juan Oliver
mTOR inhibitors and kidney 
growth in autosomal dominant 
polycystic kidney disease
Walz et al., N Engl J Med advance online publication, 26 June 2010, 
doi:10.1056/NEJMoa1003491
Serra et al., N Engl J Med advance online publication, 26 June 2010, 
doi:10.1056/NEJMoa0907419
Two articles deal with the potential therapy of autosomal 
dominant polycystic kidney disease (ADPKD) with the mTOR 
inhibitors everolimus and sirolimus. ADPKD is the most com-
mon hereditary kidney disease, characterized by a slowly pro-
gressive course that usually leads to end-stage renal disease at 
varying ages. Although the underlying gene mutations were 
identified several years ago, efficacious therapy to curtail cyst 
growth and prevent renal failure is not available. Experimental 
and observational studies suggest that the mammalian target of 
rapamycin (mTOR) pathway plays a critical role in cyst growth. 
Observations of transplant patients with polycystic liver and 
kidney involvement who are receiving rapamycin (sirolimus) 
for immunosuppression noted that both liver and kidney cyst 
volumes decreased during the rapamycin treatment. Further-
more, studies in genetic animal models of polycystic kidney 
disease (PKD) treated with rapamycin showed a slowing down 
of the progression of the renal insufficiency and the cyst vol-
ume. Also, in patients with PKD, cyst volume correlates well 
with the progression of the renal disease. These observations 
prompted two groups to examine the effects of everolimus and 
sirolimus, respectively, on the progression of cyst volume and 
glomerular filtration rate in patients with ADPKD. Walz et al. 
performed a 2-year, double-blind trial, in which they randomly 
assigned 433 patients with ADPKD to receive either placebo 
or the mTOR inhibitor everolimus. The primary outcome was 
the change in total kidney volume, as measured on magnetic 
resonance imaging, at 12 and 24 months. Their results show 
that total kidney volume increased between baseline and 1 year 
by 102 ml in the everolimus group versus 157 ml in the placebo 
Immunoblot of the γ-subunit of the epithelial sodium channel (γ-ENaC; 
top) and of aquaporin 2 (AQP2; bottom) in the renal cortex of wild-type 
(WT) and mPGES-1–/– (KO) mice after 2-week treatment with vehicle or 
aldosterone.
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group and between baseline and 2 years by 230 ml and 301 ml, 
respectively. Cyst volume increased by 76 ml in the everolimus 
group and 98 ml in the placebo group after 1 year and by 181 
ml and 215 ml, respectively, after 2 years. Parenchymal volume 
increased by 26 ml in the everolimus group and 62 ml in the 
placebo group after 1 year and by 56 ml and 93 ml, respectively, 
after 2 years. The mean decrement in the estimated glomerular 
filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 
of body-surface area in the everolimus group versus 7.7 ml per 
minute in the placebo group. Drug-specific adverse events were 
more common in the everolimus group; the rate of infection 
was similar in the two groups. Walz et al. conclude that within 
the 2-year study period, everolimus slowed the increase in total 
kidney volume of patients with ADPKD but did not slow the 
decline in progressive renal impairment.
The results of the second study, conducted by Serra et al. and 
performed with sirolimus, are mostly in agreement with those of 
Walz et al. In this 18-month, open-label, randomized, controlled 
trial, Serra et al. randomly assigned 100 patients between the 
ages of 18 and 40 years to receive either sirolimus or standard 
care. All patients had an estimated creatinine clearance of at 
least 70 ml per minute. Serial magnetic resonance imaging was 
performed to measure the volume of polycystic kidneys. The 
primary outcome was total kidney volume at 18 months on 
blinded assessment. Secondary outcomes were the glomerular 
filtration rate and urinary albumin excretion rate at 18 months. 
At ran domization, the median total kidney volume was 907 cm3 
(interquartile range, 577–1330) in the sirolimus group and 1003 
cm3 (interquartile range, 574–1422) in the control group. The 
median increase over the 18-month period was 99 cm3 (inter-
quartile range, 43–173) in the sirolimus group and 97 cm3 
(interquartile range, 37–181) in the control group. At 18 months, 
the median total kidney volume in the sirolimus group was 102% 
of that in the control group (95% confidence interval, 99–105). 
The glomerular filtration rate did not differ sig nificantly between 
the two groups; however, the urinary albumin excretion rate was 
higher in the sirolimus group.
Unfortunately, then, these two studies provide no evidence 
that the mTOR inhibitors sirolimus and everolimus can effec-
tively slow down the progression of renal insufficiency in 
patients with ADPKD. Although the treatment may initially 
retard the growth of renal cysts in some patients, this, unfor-
tunately, does not translate into improved outcome as far as 
decline in glomerular filtration rate is concerned. Also, the fre-
quent occurrence of stomatitis as a side effect, already noted in 
a similar, but small, pilot study by Perico et al.,1 and the increase 
in proteinuria observed with the treatment do not encourage the 
long-term use of these drugs as treatment for ADPKD. Though 
these results are disappointing, both groups should be congratu-
lated on having performed these excellent and state-of-the-art 
clinical studies, which also show again that appropriately pow-
ered therapeutic studies can and should be performed in renal 
diseases and that the renal community should no longer accept 
uncontrolled observational studies.
Detlef Schlöndorff
1J Am Soc Nephrol 2010; 21: 1031–1040.
Epithelial cell cycle arrest in G2/M 
mediates kidney fibrosis after injury
Yang et al., Nat Med 2010; 16: 535–543; doi:10.1038/nm.2144
When acute kidney injury (AKI) occurs, normal tissue repair 
mechanisms usually are able to restore proper kidney function, 
provided the injury is discovered quickly and treated success-
fully. However, if these repair mechanisms are disrupted or the 
injury-causing irritants persist, AKI can progress into a chronic 
disorder, characterized by marked organ remodeling and fibro-
sis. The mechanism that triggers the fibrogenic response after 
injury is not well understood. In a recent landmark paper, Yang 
et al. used three different models of AKI—ischemic (moder-
ate and severe), toxic (aristolochic acid), and obstruction—to 
demonstrate a causal association between epithelial cell cycle 
G2/M arrest and a fibrotic outcome. G2/M-arrested proximal 
tubular cells activate c-jun NH2-terminal kinase (JNK) signal-
ing, which acts to upregulate profibrotic cytokine production. 
Treatment with a JNK inhibitor, bypassing of the G2/M arrest 
by administration of a p53 inhibitor (pifithrin-α), or removal 
of the contra lateral kidney rescues fibrosis in the unilateral 
ischemic injured kidney. It is possible that normal nonfibrotic 
repair depends on efficient dedifferentiation of the surviving 
epithelial cells, which is dependent on reduced p53–p21 path-
way activation.1,2
Hence, epithelial cell cycle arrest at G2/M and its subsequent 
downstream signaling are hitherto unrecognized therapeutic 
targets for the prevention of fibrosis and interruption of the 
accelerated progression of kidney disease (Figure).
Marc De Broe
1Nature 2009; 460: 1132–1135. 2Nature 2009; 460: 1140–1144. 3Nat Med 2010; 16: 
523–525. 
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Epithelial cell cycle arrest in G2/M and epigenetic changes in fibroblasts 
coordinately promote kidney fibrosis.3 
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